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Abstract: The aim of the present study is to assess and compare the frequencies of the cytochrome P450 CYP2C9 varia­
tions in the Baluch ethnic group (n=110) with other ethnic groups. The allele frequencies of CYP2C9*1, CYP2C9*2 and
CYP2C9*3 were 80.90%, 11.82% and 7.27%, respectively. 70.90%, 11.82%, 8.18%, 4.55%, 2.73% and 1.82% of subjects
were with CYP2C9*1/*1, CYP2C9*1/*2, CYP2C9*1/*3, CYP2C9*2/*2, CYP2C9*2/*3 and CYP2C9*3/*3 genotypes,
respectively. Different mutants may effect on prediction of drug dose requirements in different ethnic groups. Thus,
CYP2C9 variants to be determined for findings high risk groups use optimal dosage of drugs metabolized by this poly­
morphic enzyme. 
Keywords: Baluch ethnic group, CYP2C9 genetic polymorphism, polymerase chain reaction–restriction fragment length
polymorphism (PCR-RFLP).
1. INTRODUCTION
The cytochrome P-450 (CYP) is responsible for the me­
tabolism of many drugs, such as warfarin, phenytoin, losar­
tan, irbesartan, tolbutamide, glipizide, torsemide, and differ­
ent nonsteroidal anti-inflammatory drugs [1]. Various single
nucleotide genetic polymorphisms for CYP2C9 have been
recognized [2, 3]. There are 3 alleles, (CYP2C9*1 (wild-type
allele), *2 and *3) in most different ethnic groups. People
with the *2 and *3 alleles show decreased enzymatic activ­
ity, and these subjects have been indicated as “poor metabo­
lizers” [4, 5] that they may tolerate drug toxicity. Therefore,
it is necessary to determine CYP2C9 genotype in different
ethnic groups to prevent drug toxicity. Study on the genotype
distribution among Caucasian populations varies for the
*1/*1, *1/*2 *1/*3*, 2/*2, *2/*3 and*3/*3 genotypes [2].
Caucasians populations have shown more allele frequencies
of CYP2C9*2 and CYP2C9*3 when compared to African-
American and Asian populations while Chinese and Japa­
nese have not indicated the CYP2C9*2 allele [6]. There has
not been any investigation on the genotype of CYP2C9 alle­
lic variants in Baluch ethnic group in Iran. Different studies
have shown that there are variation in the distribution of po­
lymorphic alleles of CYP2C9 between Iranian ethnic groups
in North and South of Iran. These studies have indicated that
the frequency of CYP2C9*3 among southern Iranians (9.8%)
and Caucasians (9.7%) were similar. The frequency of
CYP2C9*3 among Africans (1%), Japanese (2.3%), and 
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northern Iranians (0%) were lower than southern Iranians
[7]. Study of Azarpira et al. also showed that the frequency 
of CYP2C9*2 (25.3%) was higher than Caucasian (10%– 
13%), African (2%), and Asian (0%) populations [7]. The
aim of the study was to assess and compare the frequencies
of the cytochrome P450 CYP2C9 alleles and genotypes in 
the Baluch ethnic group with the frequencies in other differ­
ent ethnic groups.
2. MATERIALS AND METHODS  
The present study contained 110 unrelated healthy
Baluch people (who speak Baluch as a native language and 
population inbreeding people) referred to Health Center in 
Chabahar, in Sistan and Baluchestan province (located in
South East of Iran). The age ranges of Baluch ethnic group 
was 14-53 years old. _The mean ages of subjects were 30/76
±11/63 years old. A five milliliters venous blood was col­
lected into EDTA tubes. DNA extraction from peripheral
white blood cells was carried out by the method of salting 
out [8]. Sterilized distilled water was used to dissolve DNA
extract and samples were stored in -20
o
C until analyzed by 
polymerase chain reaction (PCR). Genotyping of CYP2C9 
alleles was done by Polymerase Chain Reaction (PCR)­
Restriction Fragment Length Polymorphism (RFLP) tech­
nique [9]. The PCR was performed in a 25 microliter reac­
tion mixture containing PCR buffer (2.5 μl (10 mM Tris– 
HCl, pH 9), 2 μl (40 Mm) MgCl2 (Fermentas), 50 mM KCl 
(Fermentas), 12.5 mM deoxyribonucleotide triphosphate
(dNTP) mix, 0.2 μl (5 U/μl) Taq polymerase (Fermentas), 1 
μl (0.4 μM) of each primer (Bioneer), 2 μl (100 ng/μl) DNA 
(Genomic) and sterile distillated water). Genetix CG palm­
thermocycler (India) was used to perform PCR. Restriction
enzymes (Fermentas) were utilized to digest PCR products
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(10μl). Restriction enzymes, Ava II and Kpn I were used for
CYP2C9*2 and CYP2C9*3 at 37oC for 16 hrs for complete
digestion. Amplification of primers was done by De Morais
et al. method [10]. Electrophorese is of the DNA fragments
(Apelex, France) was performed on a 3% agarose gel and 
Ethidium bromide was utilized to stain the gel. Detected
Bands were photographed using a Polaroid Gel Camera with 
black and white film (not shown). For detection of the
CYP2C9*2 mutation, sense primer (5'-
CACTGGCTGAAAGAGCTAACAGAG-3') and antisense
primer (5'-GTGATATGGAGTAGGGTCACCCAC-3') were
used. The CYP2C9*3 mutation detection was done using 
sense primer 5'-TGCACGAGGTCCAGAGGTAC-3' and
antisense primer 5'-ACAAACTTACCTTGGGAATGAGA-
3'. The conditions of PCR amplification were as follows: For 
CYP2C9*2: Initial denaturation, Number of cycle(s), De-
naturation, annealing, Extention and final extention step
were 95oC, 10 min.; 40; 95oC, 5 sec.; 65 oC, 30 sec.; 72oC, 30
sec. and 72oC, 5 min. and for CYP2C9*3: 94oC, 5 min.; 30; 
94 oC, 45 sec.; 63 oC, 45 sec.; 72 oC, 30 sec. and 72oC, 5 min.,
respectively. 95% confidence intervals (95% CI) were per-
formed to determine the frequency of the variant alleles of
each gene. Fisher exact test was used to evaluate variations
in allele and genotype frequencies between Baluch ethnic
groups and different other population.
3. RESULTS 
The distribution of genotype and allelic frequencies of
CYP2C9 among Baluch ethnic group are shown in Table 1. 
The allele frequency of CYP2C9*1 (Wild type), CYP2C9*2
and CYP2C9*3 were 80.90% (95% CI: 73.55-88.24),
11.82% (95% CI: 5.78-17.82) and 7.27% (95% CI: 2.44-
12.16), respectively (Table 1). The frequencies of CYP2C9
genotypes in Baluch ethnic group were found to be 70.90%
of subjects with CYP2C9*1/*1 genotype (95% CI: 62.41-
79.38). 11.82%, 8.18%, 4.55%, 2.73 and 1.82 subjects with
CYP2C9*1/*2 (95% CI: 5.78-17.84), CYP2C9*1/*3(95%
CI: 3.06-13.30), CYP2C9*2/*2(95% CI: 0.65-8.43),
CYP2C9*2/*3 (95% CI: 0-5.77) and CYP2C9*3/*3(95%
CI: 0-4.30) genotypes, respectively (Table 1). Tables 2 and
3 show the distribution of CYP2C9 genotype and allele fre-
quency in Baluch ethnic group and in different populations.
4. DISCUSSION
Variations in CYP expression among different ethnic
groups make it important in drug response, activity and de-
toxification. It is been shown that there are three major vari-
ants of the CYP2C9 gene in different ethnic groups. It is
reported that there are three major variants of the CYP2C9
gene in Caucasian populations [11]. CYP2C9*2 and 
CYP2C9*3 allelic variants show almost 10–40% and 5–15%
of the activity of CYP2C9*1 for various drug, respectively 
[12-15]. The allelic frequency of CYP2C9*2 found in the
present study was 11.82% (almost similar to the Iranian 
Fars) [16] which was higher than Japanese [24], African
[25], Pakistanis [26], Tamilians [27], Keralans [28], Chinese
[29] and Korean [30] populations (Table 2). Our results
show that the CYP2C9*2 variant was more frequent than
above mentioned populations. In our study group, the allelic
frequency of CYP2C9*3 was 7.27%. The frequency of
CYP2C9*3 was almost similar to the frequencies found in 
Italians [17], Greeks [18], Swedish [20], Pakistanis [26] and 
Keralans [28] (Table 2). Genetic differences in the CYP2C9
make it possible that some drugs such as warfarin metabolize
differently. Single-nucleotide polymorphisms in CYP2C9 
influence metabolism of this drug. Clinicians can appraise
optimal warfarin dose by genotyping subjects for single-
nucleotide polymorphisms. Subjects who have the
CYP2C9*2 and/or CYP2C9*3 variants metabolize warfarin 
more in a different manner than subjects without these vari-
ants. It has been shown that CYP2C9 genotype estimates
warfarin optimal dosage in subjects on warfarin treatment 
[30]. Distribution of CYP2C9 genotypes in Baluch and dif-
ferent ethnic groups has been shown in Table 3. Our geno-
type results have shown that frequency of *1/*2 and *1/*3 
was 11.82% and 8.18% which was higher [24-30] and lower 
[16-21, 23 and 26-28] than other populations, respectively.
The prevalence of CYP2C9*2/*2 (except Iranian Turkmen 
[16]), *2/*3 and *3/*3 genotypes in Iranian Baluch ethnic
group were higher when compared with different other eth-
nic groups [16-30]. Many studies have indicated that*2/*2
[24-29, 6], *2/*3 [16, 22-29 and 6] and *3/*3 [16, 18, 21, 22,
25, 27 and 29, 6] genotype frequency was not detectable in 
some populations. CYP2C9*3/*3 genotype is contributed
with some important clinical variations in the pharmacoki-
netics of CYP2C9 substrates. 
Table 1. Genotype and Allelic frequencies of CYP2C9 in the Baluch ethnic group.
CYP2C9 genotypes Number (%) 95% CI CYP2C9 alleles Number (%) 95% CI
*1/*1 78(70.90) 62.41-79.38 *1 89(80.90) 73.55-88.24 
*1/*2 13(11.82) 5.78-17.84 *2 13(11.82) 5.78-17.82
*1/*3 9(8.18) 3.06-13.30 *3 8(7.27) 2.44-12.16
*2/*2 5(4.55) 0.65-8.43 
*2/*3 3(2.73) 0-5.77 
*3/*3 2(1.82) 0-4.30 
Total 110 (100)
*Means separation of effective alleles.
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Table 2. Comparison of allele frequencies of CYP2C9 in Baluch ethnic group with different populations.
Population study
Sample size
(n) 
Allele frequency of
*1(%) 
Allele frequency of
*2(%) 
Allele frequency of
*3(%) 
References
Iranian Baluch 110 80.90 11.82 7.27 Present study 
Iranian Fars 140 83 11(NS) 6(NS) 16 
Iranian Turkmen 140 88 8(NS) 4(NS) 16 
Italian 360 77.7 12.5(NS) 9.7(NS) 17 
Greek 283 79 12.8(NS) 8.1(NS) 18 
Russians 290 82.7 10.5(NS) 6.7 (NS) 19 
Swedish 430 81.9 10.6(NS) 7.4(NS) 20 
Slovenia 129 81.7 12(NS) 6.2(NS) 21 
UK 561 84.1 10.6(NS) 5.2 (NS) 22 
Egyptians 247 81.7 11.8(NS) 6.2(NS) 23 
Japan 828 97.6 0(0.001) 2.3(0.004) 24 
African 47 9 2(0.004) 1 (<0.0001) 25 
Pakistan 120 91.6 0.8(0.001) 7.5(NS) 26 
Tamilians 135 90.7 2.6(0.0045) 6.7(NS) 27
Kerala 120 90 2.0(0.0011) 8.0 (NS) 28 
Chinese 115 98.3 0(0.001) 1.7(<0.0001) 29 
Korean 574 98.9 0 (0.001) 1.1(<0.0001) 30 
Differences in the allele frequencies were determined by Fisher exact test. NS: No significant differences.
 
P-value versus Baluch ethnic group.
 
*Means separation of effective alleles.
 
Table 3. Comparison of CYP2C9 genotype frequency in Baluch ethnic group with different populations.
Population
study
Sample
size
(n) 
Genotype
frequency of
*1/*1(%)
Genotype
frequency of
*1/*2(%)
Genotype
frequency of
*1/*3(%)
Genotype
frequency of
*2/*2(%)
Genotype
frequency of
*2/*3(%)
Genotype
frequency of
*3/*3(%)
References
Iranian
Baluch
110 70.90 11.82 8.18 4.55 2.73 1.82 
Present
study
Iranian
Fars 
140 70(NS) 14.55(NS) 10.91(NS) 2.73(0.011) 1.82(NS) 0(0.001) 16 
Iranian
Turkmen
140 37.9(<0.0001) 42.1(<0.0001) 9.3(NS) 9.3(<0.0001) 0 1.4(NS) 16 
Italian 360 62(NS) 17.2(NS) 14.5(0.014) 2.7(0.011) 2.2(NS) 1.3(NS) 17 
Greek 283 62(NS) 20(NS) 13.5(0.014) 1.5(0.001) 2.8(NS) 0(0.001) 18 
Russians 290 68(NS) 18.2(NS) 10.3(NS) 0.6(<0.0001) 1.2(0.011) 0.3(0.0085) 19 
Swedish 430 66.7(NS) 18.6(NS) 11.6(NS) 0.4(<0.0001) 1.6(0.011) 0.6(0.0095) 20 
Slovenia 129 86.6(<0.0016) 19.3(NS) 10.8(NS) 1.5(0.001) 1.5(0.011) 0(0.001) 21 
UK 561 69.9(NS) 19(NS) 0.06(<0.0001) 0.003(<0.0001) 0(<0.0001) 0(0.001) 22 
Egyptians 247 66.3(NS) 19(NS) 12(NS) 2.4(0.011) 0(<0.0001) 0.4(0.0088) 23 
Japan 828 95(<0.0001) 0(<0.0001) 4(<0.001) 0(<0.0001) 0(<0.0001) 1(NS) 24 
African 47 93.6(<0.0001) 4.2(0.014) 2.1(<0.001) 0(<0.0001) 0(<0.0001) 0(0.001) 25 
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(Table 3) contd…. 
Population
study
Sample
size
(n) 
Genotype
frequency of
*1/*1(%)
Genotype
frequency of
*1/*2(%)
Genotype
frequency of
*1/*3(%)
Genotype
frequency of
*2/*2(%)
Genotype
frequency of
*2/*3(%)
Genotype
frequency of
*3/*3(%)
References
Pakistan 120 85.8(<0.0011) 0(<0.0001) 11.7(NS) 0.8(<0.0001) 0(<0.0001) 1.7(NS) 26 
Tamilians 135 82.3(NS) 4.4(0.017) 12.7(NS) 0(<0.0001) 0.7(<0.0001) 0(0.001) 27 
Kerala 120 81.0(NS) 4.0(0.011) 14.0(0.014) 0(<0.0001) 0(<0.0001) 1.0(NS) 28 
Chinese 115 97.0(<0.0001) 0(<0.0001) 3.0(<0.001) 0(<0.0001) 0(<0.0001) 0(0.001) 29 
Korean 574 97.7(<0.0001) 0(<0.0001) 2.3(<0.001) 0(<0.0001) 0(<0.0001) 0(0.001) 30 
Differences in the genotype frequencies were determined by Fisher exact test. NS: No significant differences. P-value versus Baluch ethnic group.
*Means separation of effective alleles.
CONCLUSION 
In conclusion, our results show that there are ethnic
variations in the CYP2C9 allele and genotype frequencies.
Genetic differences in the CYP2C9 were seen in Iranian
Baluch. The presence of different mutant genotypes and al­
leles may effect on prediction of drug dose requirements in 
different ethnic groups. Thus, it requires that CYP2C9 vari­
ants determination in different populations may help high
risk groups to use optimal dosage of drugs metabolized by
this polymorphic enzyme.
CONFLICT OF INTEREST
The authors confirm that this article content has no con­
flict of interest.
ACKNOWLEDGEMENTS
Declared none.
REFERENCES
[1] 	 Lee, C.R.; Goldstein, J.A.; Pieper, J.A. Cytochrome P450 2C9
Polymorphisms: A comprehensive review of the in-vitro and hu­
man datam. Pharmacogenetics, 2002, 3, 251-263.  
[2]	 Si, D.; Guo, Y.; Zhang, Y.; Yang, L.; Zhou, H.; Zhong, D. Identifi­
cation of a novel variant CYP2C9 Allele in Chinese. Pharmacoge-
netics, 2004, 7, 465-469.
[3]	 Maekawa, K.; Harakawa, N.; Sugiyama, E.; Tohkin, M.; Kim, S.,
R.; Kaniwa, N.; Katori, N.; Hasegawa, R.; Yasuda, K.; Kamide, K.;
Miyata, T.; Saito, Y.; Jun-ichi S. Substrate-dependent functional al­
terations of seven CYP2C9 variants found in Japanese subjects.
Drug Metab. Disposit., 2009, 9, 1895-1903.
[4] 	 Aithal, G. P.; Day, C.P.; Kesteven, P.J.; Daly, A.K. Association of
polymorphisms in the Cytochrome P450 CYP2C9 with Warfarin 
dose requirement and risk of bleeding complications. Lancet, 1999, 
9154, 717-719.
[5]	 Schwarz, U.I. Clinical relevance of genetic polymor-phisms in the
human CYP2C9 Gene. Eur. J. Clin. Invest., 2003, 2, 23-30.
[6]	 Yoon, Y.R.; Shon, J.H.; Kim, M.K.; Lim, Y., C.; Lee, H., R.; Park,
J., Y.; Cha, I-J.; Shin, J-G. Frequency of cytochrome P450 2C9
mutant alleles in a Korean population. Br. J. Clin. Pharmacol.,
2001, 3, 277- 280.
[7] 	 Azarpira, N.; Namazi, S.; Hendijani, F.; Banan, M.; Darai, M.
Investigation of allele and genotype frequencies of CYP2C9,
CYP2C19 and VKORC1 in Iran. Pharmacol Rep., 2010, 62, 740­
746.
[8] 	 Miller, S.A.; Dykes, D.D.; Polesky, H.F. A simple salting out pro­
cedure for extracting DNA from human nucleated cells. Nucleic 
Acids Res., 1988, 3, 1215.
[9] 	 Brosen, K.; de Morais, S.M.; Meyer, U.A.; Goldstein, J.A.  A 
multifamily study on the relationship between CYP2C19 genotype
and S-mephenytoin oxidation phenotype. Pharmacogenetics.,
1995, 5, 312-7.
[10]	 De Morais, S.M.; Wilkinson, G.R.; Blaisdell, J.; Meyer, U.A.;
Nakamura, K.; Goldstein, J.A. Identification of a new genetic de­
fect responsible for the polymorphism of (S)-mephenytoin metabo­
lism in Japanese. Mol. Pharmacol., 1994, 4, 594- 598.
[11]	 Miners, J.O.; Birkett, D.J. Cytochrome P4502C9: an enzyme of
major importance in human drug metabolism. Br. J. Clin. Pharma-
col., 1998, 45, 525-38.
[12]	 Rettie, A.E.; Wienkers, L.C.; Gonzalez, F.J.; Trager, W.F.;
Korzewka, K.R. Impaired (S)-warfarin metabolism catalysed by the
R144C allele variant of CYP2C9. Pharmacogenetics., 1994, 4, 39­
42.
[13]	 Haining, R.L.; Hunter, A.P.; Veronese, M.E.; Trager, W.F.; Rettie,
A.E. Allele variants of human cytochrome P450 2C9: baculovirus­
mediated expression, purification, structural characterization, sub­
strate stereoselectivity, and prochiral selectivity of the wild-type
and I359L mutant forms. Arch. Biochem. Biophys., 1996, 333, 447­
58.
[14]	 Takanashi, K.; Tainaka, H.; Kobayashi, K.; Yasumori, T.; Hosa­
kama, M.; Chiba, K. CYP2C9 Ile359 and Leu359 variants: enzyme
kinetic study with seven substrates. Pharmacogenetics., 2000, 10, 
95-104.
[15]	 Thijssen, H.H.; Ritzen, B. Acenocumarol pharmacokinetics in
relation to cytochrome P450 2C9 genotype. Clin. Pharmacol. 
Ther., 2003, 74, 61-8. 
[16]	 Agh A.O.; Ghiyas T.R.; Mansourian, A.R.; Samai, N.M.; Marjani,
A. Genetic polymorphism of cytochrome P450 2C9 (CYP2C9) in
two ethnic groups in Iran. Am. J. Biomed. Sci, 2013, 3, 177-187.
[17]	 Scordo, M.G.; Caputi, A.P.; D’Arrigo, C.; Fava, G.; Spina, E. Al­
lele and genotype frequencies of CYP2C9, CYP2C19 and CYP2D6
in an Italian population. Pharmacol. Res., 2004, 50, 195-200.
[18]	 Arvanitidis, K.; Ragia, G.; Iordanidou, M.; Kyriaki, S.; Xanthi, A.;
Tavridou, A.; Manolopoulos, V.G. Genetic polymorphisms of
drug-metabolizing enzymes CYP2D6, CYP2C9, CYP2C19 and
CYP3A5 in the Greek population. Fundam. Clin. Pharmacol.,
2007, 21, 419-426.
[19]	 Gaikovitch, E.A.; Cascorbi, I.; Mrozikiewicz, P.M.; Brockmöller,
J.; Frötschl, R.; Köpke, K.; Gerloff, T.; Chernov, J.N.; Roots, I. Po­
lymorphisms of drug-metabolizing enzymes CYP2C9, CYP2C19,
CYP2D6, CYP1A1, NAT2 and of P-glycoprotein in a Russian 
population. Eur. J. Clin. Pharmacol., 2003, 59, 303-312.
[20]	 Yasar, U.; Eliasson, E.; Dahl, M.L.; Johansson, I.; Ingelman-
Sundberg, M.; Sjöqvist, F. Validation of methods for CYP2C9
genotyping: frequencies of mutant alleles in a Swedish population.
Biochem. Biophys. Res. Commun., 1999, 254, 628-631.  
[21]	 Herman, D.; Dolzan, V.; Breskvar, K. Genetic polymorphism of
cytochromes P450 2C9 and 2C19 in Slovenian population. Zdrav.
Vestn., 2003, 72, 347-351.
[22]	 Sconce, E.A.; Khan, T.I.; Wynne, H.A.; Avery, P.; Monkhouse, L.;
King, B.P.; Wood, P.; Kesteven, P.; Daly, A.K.; Kamali, F.  The
impact of CYP2C9 and VKORC1 genetic polymorphism and patient
characteristics upon warfarin dose requirements: proposal for a new
dosing regimen. Blood, 2005, 106, 2329-2333.
[23]	 Hamdy, S.I.; Hiratsuka, M.; Narahara, K.; El-Enany, M.; Moursi,
N.; Ahmed, M.S.; Mizugaki, M. Allele and genotype frequencies of
          
 
 
  
  
   
    
  
 
  
  
   
  
 
   
  
 
  
 
  
 
  
  
 
  
 
  
   
  
   
 
   
  
 
 
 
Genetic Polymorphisms of CYP2C9 in the Baluch Ethnic Group	 The Open Biochemistry Journal, 2015, Volume 9 41
polymorphic cytochromes P450 (CYP2C9, CYP2C19, CYP2E1)
and dihydropyrimidine dehydrogenase (DPYD) in the Egyptian
population. Br. J. Clin. Pharmacol., 2002, 53, 596-603.  
[24]	 Mushiroda, T.; Ohnishi, Y.; Saito, S.; Takahashi, A.; Kikuchi, Y.;
Saito, S.; Shimomura, H.; Wanibuchi, Y.; Suzuki, T.; Kamatani,
N.; Nakamura, Y. Association of VKORC1 and CYP2C9 polymor­
phisms with warfarin dose requirements in Japanese patients. J.
Hum. Genet., 2006, 51, 249-253.  
[25]	 Isaza, C.; Henao, J.; Martínez, J.H.; Arias, J.C.; Beltrán, L. Pheno­
type-genotype analysis of CYP2C19 in Colombian mestizo indi­
viduals. BMC. Clin. Pharmacol., 2007, 7, 6.
[26]	 Siddiqi, A.; Khan, D.A.; Khan, F.A.; Khaliq N.A. Impact of
CYP2C9 genetic polymorphism on warfarin dose requirements in
Pakistani population. Pak. J. Pharm. Sci., 2010, 4, 417-422.
[27]	 Adithan, C.; Gerard, N.; Vasu, S.; Balakrishnan, R.; Shashindran,
C.H.; and Krishnamoorthy, R. Allele and genotype frequency of
CYP2C9 in Tamilnadu population. Eur. J Clin. Pharmacol., 2003, 
59, 707-709.
[28]	 Jose, R.; Chandrasekaran, A.; Sam, S.S.; Gerard, N.; Chanolean, S.;
Abraham,  B.K.; Satyanarayanamoorthy, K.; Peter, A.; Rajagopal,
K. CYP2C9 and CYP2C19 genetic polymorphisms: frequencies in
the south Indian population. Fundam. Clin. Pharmacol., 2005, 19, 
101-105.
[29]	 Wang, S.L.; Huang, J.; Lai, M.D.; Tsai, J.J. Detection of CYP2C9
polymorphism based on the polymerase chain reaction in Chinese.
Pharmacogenetics., 1995, 5, 37-42.
[30]	 Moridani, M.; Fu, L.; Selby, R.; Yun, F.; Sukovic, T.; Wong, B.;
Cole, D., E. Frequency of CYP2C9 polymorphisms affecting war­
farin metabolism in a large anticoagulant clinic cohort. Clin. Bio-
chem., 2006, 36, 606-612.
Received: January 28, 2015 Revised: May 10, 2015 Accepted: May 11, 2015
 
© Tabari et al.; Licensee Bentham Open.
 
This is an open access article licensed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/­
licenses/by-nc/3.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.
 
